Attached files
| file | filename |
|---|---|
| 10-Q - EDGE THERAPEUTICS INC 10-Q 3-31-2016 - PDS Biotechnology Corp | form10q.htm |
| EX-31.1 - EXHIBIT 31.1 - PDS Biotechnology Corp | ex31_1.htm |
| EX-10.1 - EXHIBIT 10.1 - PDS Biotechnology Corp | ex10_1.htm |
| EX-32.2 - EXHIBIT 32.2 - PDS Biotechnology Corp | ex32_2.htm |
| EX-31.2 - EXHIBIT 31.2 - PDS Biotechnology Corp | ex31_2.htm |
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Edge Therapeutics, Inc. (the “Company”), on Form 10-Q for the quarter ended March 31, 2016 (the “Report”), I, Brian A. Leuthner, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
| (1) | the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Dated: May 3, 2016
|
/s/ Brian A. Leuthner
|
|
|
Brian A. Leuthner
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|